ZEVRA THERAPEUTICS INC

ZEVRA Therapeutics insider buys 66,667 shares—signaling exec confidence in rare‑disease pipeline and near‑term upside for investors.

Ze vra’s new equity grant to senior finance executive signals long‑term confidence in its rare‑disease pipeline, aligning incentives, preserving cash, and boosting shareholder trust.

CEO buys 37,500 shares of Zevra Therapeutics, signaling confidence in its fast‑track drug Miplyffa and boosting investor optimism.

Insider sale at Zevra shows cash‑flow planning, not panic—investors see a confidence boost from rising holdings while monitoring liquidity.